|
1
|
Brown RL, de Souza JA and Cohen EE:
Thyroid cancer: burden of illness and management of disease. J
Cancer. 2:193–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pitoia F, Bueno F, Urciuoli C, Abelleira
E, Cross G and Tuttle RM: Outcomes of patients with differentiated
thyroid cancer risk-stratified according to the American thyroid
association and Latin American thyroid society risk of recurrence
classification systems. Thyroid. 23:1401–1407. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thompson L: World Health Organization
classification of tumours: pathology and genetics of head and neck
tumours. Ear Nose Throat J. 85:742006.PubMed/NCBI
|
|
4
|
Nikiforova MN and Nikiforov YE: Molecular
genetics of thyroid cancer: implications for diagnosis, treatment
and prognosis. Expert Rev Mol Diagn. 8:83–95. 2008. View Article : Google Scholar
|
|
5
|
Carvalho C, Santos RX, Cardoso S, et al:
Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem.
16:3267–3285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Silber JH and Barber G:
Doxorubicin-induced cardiotoxicity. N Engl J Med. 333:1359–1360.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
King PD and Perry MC: Hepatotoxicity of
chemotherapy. Oncologist. 6:162–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Ni J, Zhou G, et al: Cloning,
expression and characterization of the human NOB1 gene. Mol Biol
Rep. 32:185–189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arcus VL, Bäckbro K, Roos A, Daniel EL and
Baker EN: Distant structural homology leads to the functional
characterization of an archaeal PIN domain as an exonuclease. J
Biol Chem. 279:16471–16478. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin Y, Peng S, Yu H, et al: RNAi-mediated
downregulation of NOB1 suppresses the growth and colony-formation
ability of human ovarian cancer cells. Med Oncol. 29:311–317. 2012.
View Article : Google Scholar
|
|
12
|
Che JP, Li W, Yan Y, et al: Expression and
clinical significance of the nin one binding protein and p38 MAPK
in prostate carcinoma. Int J Clin Exp Pathol. 6:2300–2311.
2013.PubMed/NCBI
|
|
13
|
Li XY, Luo QF, Li J, et al: Clinical
significance of NOB1 expression in breast infiltrating ductal
carcinoma. Int J Clin Exp Pathol. 6:2137–2144. 2013.PubMed/NCBI
|
|
14
|
Li Y, Ma C, Qian M, Wen Z, Jing H and Qian
D: Downregulation of NOB1 suppresses the proliferation and tumor
growth of non-small cell lung cancer in vitro and in vivo. Oncol
Rep. 31:1271–1276. 2014.PubMed/NCBI
|
|
15
|
Huang WY, Chen DH, Ning L and Wang LW:
siRNA mediated silencing of NIN1/RPN12 binding protein 1 homolog
inhibits proliferation and growth of breast cancer cells. Asian Pac
J Cancer Prev. 13:1823–1827. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu Z, Guo Q, Shi A, et al: Downregulation
of NIN/RPN12 binding protein inhibit the growth of human
hepatocellular carcinoma cells. Mol Biol Rep. 39:501–507. 2012.
View Article : Google Scholar
|
|
17
|
Lin S, Meng W, Zhang W, et al: Expression
of the NOB1 gene and its clinical significance in papillary thyroid
carcinoma. J Int Med Res. 41:568–572. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meng W, Wang PS, Liu J, et al:
Adenovirus-mediated siRNA targeting NOB1 inhibits tumor growth and
enhances radiosensitivity of human papillary thyroid carcinoma in
vitro and in vivo. Oncol Rep. 32:2411–2420. 2014.PubMed/NCBI
|
|
19
|
Abe S, Nishimoto Y, Isu K, Ishii T and
Goto T; Japanese Musculoskeletal Oncology Group. Preoperative
cisplatin for initial treatment of limb osteosarcoma: its local
effect and impact on prognosis. Cancer Chemother Pharmacol.
50:320–324. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao BX, Sun YB, Wang SQ, et al: Grape
seed procyanidin reversal of P-glycoprotein associated multi-drug
resistance via down-regulation of NF-κB and MAPK/ERK mediated YB-1
activity in A2780/T cells. PLoS One. 8:e710712013. View Article : Google Scholar
|
|
21
|
el-Deiry WS: Role of oncogenes in
resistance and killing by cancer therapeutic agents. Curr Opin
Oncol. 9:79–87. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tone Y and Toh-E A: Nob1p is required for
biogenesis of the 26S proteasome and degraded upon its maturation
in Saccharomyces cerevisiae. Genes Dev. 16:3142–3157. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tone Y, Tanahashi N, Tanaka K, Fujimuro M,
Yokosawa H and Toh-E A: Nob1p, a new essential protein, associates
with the 26S proteasome of growing Saccharomyces cerevisiae cells.
Gene. 243:37–45. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu G, Bernaudo S, Fu G, et al: Cyclin G2
is degraded through the ubiquitin-proteasome pathway and mediates
the antiproliferative effect of activin receptor-like kinase 7. Mol
Biol Cell. 19:4968–4979. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pandit B and Gartel AL: Thiazole
antibiotic thiostrepton synergize with bortezomib to induce
apoptosis in cancer cells. PLoS One. 6:e171102011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Piperdi B, Ling YH, Liebes L, Muggia F and
Perez-Soler R: Bortezomib: understanding the mechanism of action.
Mol Cancer Ther. 10:2029–2030. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dick LR and Fleming PE: Building on
bortezomib: second-generation proteasome inhibitors as anti-cancer
therapy. Drug Discov Today. 15:243–249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Elbashir SM, Harborth J, Weber K and
Tuschl T: Analysis of gene function in somatic mammalian cells
using small interfering RNAs. Methods. 26:199–213. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou J, Xu T, Yan Y, et al: MicroRNA-326
functions as a tumor suppressor in glioma by targeting the Nin one
binding protein (NOB1). PLoS One. 8:e684692013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li W, Liu M, Feng Y, et al: Downregulated
miR-646 in clear cell renal carcinoma correlated with tumour
metastasis by targeting the nin one binding protein (NOB1). Br J
Cancer. 111:1188–1200. 2014. View Article : Google Scholar : PubMed/NCBI
|
